Copyright
©The Author(s) 2021.
World J Cardiol. Jan 26, 2021; 13(1): 28-37
Published online Jan 26, 2021. doi: 10.4330/wjc.v13.i1.28
Published online Jan 26, 2021. doi: 10.4330/wjc.v13.i1.28
Table 2 Monitoring and prevention strategies for anthracycline-induced cardiotoxicity
| Method | Description |
| Biomarkers | Serial measurement of troponin and brain natriuretic peptide |
| Imaging studies | Regular monitoring of left ventricular function with echocardiogram or cardiac MRI |
| Pharmacologic agents | Concurrent use of dexrazoxane (for patients receiving doxorubicin ≥ 250 mg/m2 or epirubicin ≥ 600 mg/m2) |
| Administration strategies | Limiting total dose of anthracycline therapy |
| Continuous infusion | |
| Divided doses | |
| Liposomal formulation |
- Citation: Chong EG, Lee EH, Sail R, Denham L, Nagaraj G, Hsueh CT. Anthracycline-induced cardiotoxicity: A case report and review of literature. World J Cardiol 2021; 13(1): 28-37
- URL: https://www.wjgnet.com/1949-8462/full/v13/i1/28.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i1.28